B-cell lymphoma 2 family and intrinsic apoptotic pathway components (BCL2 family)

The B-cell lymphoma 2 (BCL2) family of proteins and the associated intrinsic apoptotic pathway components are central regulators of programmed cell death (apoptosis) triggered by internal cellular stress (StatPearls, 2023). This family is divided into three functional groups: anti-apoptotic proteins (e.g., BCL-2, BCL-XL, MCL-1), pro-apoptotic effectors (BAX, BAK), and pro-apoptotic BH3-only initiators (e.g., BIM, PUMA, NOXA) (Nature Reviews Cancer, 2020). In healthy cells, a delicate balance between these groups maintains survival, but in many malignancies, anti-apoptotic proteins are upregulated to prevent cell death despite DNA damage or oncogenic signaling (Cell Death & Differentiation, 2019). Therapeutic strategies primarily involve BH3 mimetics, such as Venetoclax, which bind to the hydrophobic grooves of anti-apoptotic proteins to release pro-apoptotic factors and induce mitochondrial outer membrane permeabilization (MOMP) (Journal of Hematology & Oncology, 2021). While highly effective in hematologic cancers like chronic lymphocytic leukemia (CLL), these therapies can lead to rapid cell death resulting in tumor lysis syndrome (TLS) or off-target effects like thrombocytopenia when BCL-XL is inhibited (Blood, 2020). Ongoing research aims to overcome resistance mechanisms, such as MCL-1 upregulation, by developing selective inhibitors for other family members or combining BCL-2 inhibitors with other targeted agents (Cancer Discovery, 2021). The intrinsic pathway is also a focus in neurodegenerative diseases and autoimmune conditions where dysregulated apoptosis contributes to pathogenesis (Frontiers in Cell and Developmental Biology, 2021). Biomarkers like BCL2 expression levels and BH3 profiling are increasingly used to predict patient response to these targeted therapies (Clinical Cancer Research, 2022).

Other names

BCL-2 family proteinsMitochondrial apoptotic pathway componentsBCL2-regulated apoptotic pathwayIntrinsic apoptosis pathway

BH3 mimetics bind to the hydrophobic groove of anti-apoptotic BCL-2 family proteins, displacing pro-apoptotic BH3-only proteins or effectors like BAX/BAK, thereby inducing mitochondrial outer membrane permeabilization and subsequent apoptosis (Nature Reviews Drug Discovery, 2023).